US FDA approves Glaxo, Theravance’s Breo Ellipta asthma drug – Reuters


Reuters

US FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters
(Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger …
GlaxoSmithKline plc (ADR) Gets FDA Approval For Breo Ellipta To Treat Asthma Bidness ETC
FDA Okays Breo Ellipta for Asthma in AdultsMedscape
Glaxo Wins U.S. Approval to Sell Breo Only to Adults With AsthmaBloomberg
WRAL Tech Wire
all 65 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.